Clinical safety profile of sotalol in patients with arrhythmias
about
QTc interval screening for cardiac risk in methadone treatment of opioid dependenceTime-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug EventsMeta-analysis of the Risk of Torsades de Pointes in patients treated with intravenous racemic sotalol.Antiarrhythmic drugs for atrial fibrillation.QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel.Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza.Drug-induced long QT syndromeCellular basis of drug-induced torsades de pointesClinical relevance and management of drug-related QT interval prolongation.Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes.Long QT syndrome: reduced repolarization reserve and the genetic link.Drug-induced arrhythmia: pharmacogenomic prescribing?Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program.Prevention of atrial fibrillation after cardiac surgery.Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.On the relationship among QT interval, atrial fibrillation, and torsade de pointes.QT variability during initial exposure to sotalol: experience based on a large electronic medical record.Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics.Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells.Keep the QT interval: it is a reliable predictor of ventricular arrhythmias.Sotalol: from "just another beta blocker" to "the prototype of class III antidysrhythmic compound".Sotalol: a novel beta-blocker with class III anti-arrhythmic activity.Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate.Reproducible induction of "atypical" torsades de pointes by programmed electrical stimulation: a novel form of sotalol-induced proarrhythmia?Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort.Actions and mechanisms of action of novel analogues of sotalol on guinea-pig and rabbit ventricular cellsTherapeutic drug monitoring: antiarrhythmic drugsManagement of Atrial Fibrillation Post Bypass Surgery with Intravenous Sotalol: A Case Study.Amiodarone use in patients with documented allergy to iodine-containing compounds.Adult Human Primary Cardiomyocyte-Based Model for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-arrhythmia Risk.Pharmacokinetics and electrophysiological effects of sotalol hydrochloride in horses.First, do no harm: QT interval screening in methadone maintenance treatment.Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study.The clinical noncompliance of oral sotalol/magnesium for prophylactic treatment of atrial fibrillation after coronary artery bypass grafting.
P2860
Q24201880-098A8504-B14C-4FAF-83E0-C42B2DBC7FB7Q28554594-32DBA675-7977-416A-931C-11F88443DF23Q31827349-0F26EAD7-4154-4A50-8584-81B936849861Q33821199-344AC135-25AD-4830-ADE3-8B567A4B7582Q33835424-244FCC7A-A386-4D28-88F6-16E5056A38D9Q34100661-265A1749-DE50-4504-B4BD-00FB2775F6F7Q34158669-8DE2C7E2-28F0-4C20-9C9B-02A45177F73CQ34358104-0718CB0F-116C-442F-8C1C-2CCE677FB874Q34786459-7CEBAA6C-B6F6-4046-8642-812A361B31C1Q35186542-805B19DA-F558-4490-9CFC-EDD2A564320AQ36173814-0AFA3117-64FE-47BA-8571-F98FB28081D2Q36335258-F28233A3-CF7C-44EC-AC7A-5FE93DFBD3D0Q36512441-C4D9621F-F338-47DA-A868-1181CEE4A81FQ36514742-0CA5519B-28FA-438D-971C-38038001C015Q36799910-0581BE31-D5C0-4186-8938-6871B7029432Q36986507-20BA48EA-B64D-49B8-B7D4-D5B403F674F9Q37008418-D152A833-04B5-48A1-8A2A-C40B904AADA1Q37463278-CAFC8115-F387-46C2-A049-1609E56F0A7EQ37495775-E32BCFB6-6793-46E2-B143-F8EE288F986EQ37613893-E83943C0-ECAF-44B2-9692-DB295A5E792AQ39018169-62AB9040-20FC-4EF1-BCCB-4651A85FAB4EQ40538787-48029E93-9A73-4CC2-9A86-75BD438F3C52Q40843456-7FEDE26B-C6AF-4599-AE12-8C8245FD998DQ40938946-F02CE84E-6806-4F8A-9C7E-C8114008D318Q42542142-3B53F344-6BBE-4E0A-9C0D-6F0192AE54CBQ42547649-F1DA9276-F83F-4AEC-82F4-0752D7A7C0E2Q42650229-C26A8C63-143B-402E-9820-9423354EA8A5Q42716887-A6828FA2-6E6E-4EC1-8EEB-00767F777665Q42780616-A7573D88-95ED-457D-8A0F-31AAFF608D94Q46255162-82BF0838-537F-41ED-B4B3-87A439AA5934Q46447905-956DC537-B6EA-4755-B1A9-E3A05E574A96Q47194598-1D21F9E4-2527-47A0-9153-11B00F66B495Q48201149-4B43A4FE-D34C-4CD1-8654-FD1FFF323E74Q50782076-B140BEF8-FA47-4AB2-AEAC-F4FF863A8EE5Q50885774-FAD1F23C-AB38-41B9-B898-9656B43DC582Q51909471-1F67B33B-B148-47DA-8BED-1943240ADE2C
P2860
Clinical safety profile of sotalol in patients with arrhythmias
description
1990 nî lūn-bûn
@nan
1990 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Clinical safety profile of sotalol in patients with arrhythmias
@ast
Clinical safety profile of sotalol in patients with arrhythmias
@en
Clinical safety profile of sotalol in patients with arrhythmias
@nl
type
label
Clinical safety profile of sotalol in patients with arrhythmias
@ast
Clinical safety profile of sotalol in patients with arrhythmias
@en
Clinical safety profile of sotalol in patients with arrhythmias
@nl
prefLabel
Clinical safety profile of sotalol in patients with arrhythmias
@ast
Clinical safety profile of sotalol in patients with arrhythmias
@en
Clinical safety profile of sotalol in patients with arrhythmias
@nl
P2093
P3181
P1476
Clinical safety profile of sotalol in patients with arrhythmias
@en
P2093
R B Spangenberg
P304
74A-81A; discussion 82A-83A
P3181
P356
10.1016/0002-9149(90)90207-H
P407
P577
1990-01-02T00:00:00Z